Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

被引：177

作者：

van de Loosdrecht, Arjan A. ^{[1
]}

Alhan, Canan ^{[1
]}

Bene, Marie Christine ^{[2
,3
]}

Della Porta, Matteo G. ^{[4
,5
]}

Drager, Angelika M. ^{[1
]}

Feuillard, Jean ^{[6
]}

Font, Patricia ^{[7
]}

Germing, Ulrich ^{[8
]}

Haase, Detlef ^{[9
]}

Homburg, Christa H. ^{[10
]}

Ireland, Robin ^{[11
]}

Jansen, Joop H. ^{[12
]}

Kern, Wolfgang ^{[13
]}

Malcovati, Luca ^{[4
,5
]}

Marvelde, Jeroen G. Te ^{[14
]}

Mufti, Ghulam J. ^{[11
]}

Ogata, Kiyoyuki ^{[15
]}

Orfao, Alberto ^{[16
,17
]}

Ossenkoppele, Gert J. ^{[1
]}

Porwit, Anna ^{[18
]}

Preijers, Frank W. ^{[12
]}

Richards, Stephen J. ^{[19
]}

Schuurhuis, Gerrit Jan ^{[1
]}

Subira, Dolores ^{[20
]}

Valent, Peter ^{[21
]}

van der Velden, Vincent H. J. ^{[14
]}

Vyas, Paresh ^{[22
,23
]}

Westra, August H. ^{[1
]}

de Witte, Theo M. ^{[12
]}

Wells, Denise A. ^{[24
]}

Loken, Michael R. ^{[24
]}

Westers, Theresia M. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[2] Nancy Univ, Fac Med, Nancy, France

[3] Nancy Univ, CHU, Nancy, France

[4] Fdn IRCCS Policlin San Matteo, Dept Hematol & Oncol, Pavia, Italy

[5] Univ Pavia, I-27100 Pavia, Italy

[6] CHU Dupuytren, Hematol Lab, Limoges, France

[7] Univ Gregorio Maranon, Dept Hematol, Gen Hosp, Madrid, Spain

[8] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[9] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany

[10] Sanquin Res CLB, Amsterdam, Netherlands

[11] Kings Coll Hosp London, London, England

[12] St Radboud Univ, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands

[13] MLL Munich Leukemia Lab, Munich, Germany

[14] Erasmus MC, Dept Immunol, Rotterdam, Netherlands

[15] Nippon Med Sch, Div Hematol, Dept Med, Tokyo 113, Japan

[16] Univ Salamanca, Serv Cent Citometria, Ctr Invest Canc, Inst Biol Celular & Mol Canc,CSIC USAL, E-37008 Salamanca, Spain

[17] Univ Salamanca, Dept Med, E-37008 Salamanca, Spain

[18] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden

[19] St James Univ Hosp, HMDS, Leeds, W Yorkshire, England

[20] Fdn Jimenez Diaz, Dept Hematol, E-28040 Madrid, Spain

[21] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria

[22] Univ Oxford, Dept Hematol, Weatherall Inst Mol Med, Oxford, England

[23] John Radcliffe Hosp, Oxford OX3 9DU, England

[24] Hematologics Inc, Seattle, WA USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 08期

关键词：

myelodysplastic syndromes; flow cytometry; standardization; ELN; consensus; CHRONIC MYELOMONOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; HUMAN-BONE-MARROW; SCORING SYSTEM; HEMATOPOIETIC-CELLS; ANTIGEN-EXPRESSION; MYELOID-LEUKEMIA; CD34(+) CELLS; IMMUNOPHENOTYPE; CLASSIFICATION;

D O I：

10.3324/haematol.2009.005801

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter Row cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.

引用

页码：1124 / 1134

页数：11

共 62 条

[1] Molecular characterization of a novel immune receptor restricted to the monocytic lineage [J].

Aguilar, H ;

Alvarez-Errico, D ;

García-Montero, AC ;

Orfao, A ;

Sayós, J ;

López-Botet, M .

JOURNAL OF IMMUNOLOGY, 2004, 173 (11) :6703-6711

[2] Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease [J].

Aivado, Manuel ;

Spentzos, Dimitrios ;

Germing, Ulrich ;

Alterovitz, Gil ;

Meng, Xiao-Ying ;

Grall, Franck ;

Giagounidis, Aristoteles A. N. ;

Klement, Giannoula ;

Steidl, Ulrich ;

Otu, Hasan H. ;

Czibere, Akos ;

Prall, Wolf C. ;

Iking-Konert, Christof ;

Shayne, Michelle ;

Ramoni, Marco F. ;

Gattermann, Norbert ;

Haas, Rainer ;

Mitsiades, Constantine S. ;

Fung, Eric T. ;

Libermann, Towia A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (04) :1307-1312

[3]

[Anonymous], 2008, WHO CLASSIFICATION T

[4] Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes.: Its value in patients without karyotypic abnormalities [J].

Arroyo, JL ;

Fernández, ME ;

Hernández, JIM ;

Orfao, A ;

San Miguel, JF ;

del Cañizo, MC .

HEMATOLOGY JOURNAL, 2004, 5 (03) :227-233

[5]

Benesch Martin, 2004, Hematology, V9, P171, DOI 10.1080/10245330410001701521

[6] World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes [J].

Bernasconi, Paolo ;

Klersy, Catherine ;

Boni, Marina ;

Cavigliano, Paola M. ;

Calatroni, Silvia ;

Giardini, Ilaria ;

Rocca, Barbara ;

Zappatore, Rita ;

Caresana, Marilena ;

Dambruoso, Irene ;

Lazzarino, Mario ;

Bernasconi, Carlo .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (03) :193-205

[7] Prognostic value of circulating CD34+ cells in myelodysplastic syndromes [J].

Cesana, Clara ;

Klersy, Catherine ;

Brando, Bruno ;

Nosari, Annamaria ;

Scarpati, Barbara ;

Scampini, Linda ;

Molteni, Alfredo ;

Nador, Guido ;

Santoleri, Luca ;

Formenti, Marta ;

Valentini, Marina ;

Mazzone, Antonino ;

Morra, Enrica ;

Cairoli, Roberto .

LEUKEMIA RESEARCH, 2008, 32 (11) :1715-1723

[8] Peripheral blood MDS score: A new flow cytometric tool for the diagnosis of myelodysplastic syndromes [J].

Cherian, S ;

Moore, J ;

Bantly, A ;

Vergilio, JA ;

Klein, P ;

Luger, S ;

Bagg, A .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 64B (01) :9-17

[9]

*CLSI, 2006, H43A2 CLSI, P1987

[10] Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome [J].

Della Porta, MG ;

Malcovati, L ;

Invernizzi, R ;

Travaglino, E ;

Pascutto, C ;

Maffioli, M ;

Gallí, A ;

Boggi, S ;

Pietra, D ;

Vanelli, L ;

Marseglia, C ;

Levi, S ;

Arosio, P ;

Lazzarino, M ;

Cazzola, M .

LEUKEMIA, 2006, 20 (04) :549-555

← 1 2 3 4 5 6 7 →